Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label Pazopanib. Show all posts
Showing posts with label Pazopanib. Show all posts
Thursday, May 17, 2012

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) - Full Text View - ClinicalTrials.gov

›
Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) - Full Text View - ClinicalTrials.gov
Wednesday, January 25, 2012

abstract: Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer

›
Objective: The purpose of this review was to provide an overview of angiogenesis, including the rationale for targeting angiogenesis ...
Monday, January 16, 2012

Access : Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I|[sol]|II trial of the AGO study group : British Journal of Cancer

›
 "Severe myelotoxicity was reported in 6 of 12 patients." Conclusion: Combining either 800 or 400   mg per day pazopanib with...
Sunday, August 22, 2010

NCCN Receives $4 Million in Oncology Research Funding from GlaxoSmithKline

›
"Pazopanib is currently approved by the FDA to treat patients with advanced renal cell carcinoma. The research grant to NCCN will eval...
Saturday, July 17, 2010

Drug Watch a heads-up on pharmaceuticals in late-stage development

›
New drugs Product type/proposed indication FDA status/notes abagovomab Menarini Group an anti-idiotype antibody, able to mimic a tumor a...
Thursday, June 24, 2010

(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor

›
"In a phase I trial, a generally well-tolerated dose was identified at which the majority of patients achieved pazopanib plasma concent...
Saturday, May 29, 2010

(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor

›
Wednesday, April 07, 2010

Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer

›
"Pazopanib therapy in combination with metronomic topotecan therapy showed significant antitumor and antiangiogenic properties in precl...